| Location |
Perugia, Umbria, Italy |
| Type |
Public Research University |
| Founded |
1308 |
| Students |
~30,000 |
| Website |
https://www.unipg.it |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Clinical Neurology, Neuroimaging |
The University of Perugia (Università degli Studi di Perugia) is one of the oldest and most prestigious universities in Italy, founded in 1308 by Emperor Henry VII of Luxembourg[@university]. Located in the historic city of Perugia in the Umbria region, this institution has maintained a continuous tradition of academic excellence for over seven centuries. The university's School of Medicine and Surgery has developed particular strength in neuroscience research, with significant contributions to the understanding of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@unipg-neuro].
The University of Perugia represents a critical hub for neurodegenerative disease research in Italy, combining basic science research with clinical translation through its affiliated hospitals. The institution's location in central Italy positions it within a network of European research collaborations that span the continent's leading neurological centers.
The University of Perugia was established in 1308, making it one of the oldest universities in the world. The founding charter was granted by Emperor Henry VII, and the university quickly developed a reputation for legal studies and medicine. The university's early emphasis on medical education laid the foundation for its continued excellence in health sciences[@university].
The School of Medicine at Perugia developed throughout the medieval and Renaissance periods, attracting scholars from across Italy and beyond. The medical school maintained particular strength in anatomy and physiology, with faculty contributing to the understanding of neurological function as early as the 16th century.
In the 20th century, the University of Perugia expanded significantly, adding new faculties and research programs. The Department of Neurology was formally established in the 1970s, consolidating the university's research efforts in neurodegenerative diseases[@perugia-neuro]. This period marked the beginning of Perugia's systematic approach to Alzheimer's and Parkinson's disease research.
¶ Department of Medicine and Surgery
The Department of Medicine and Surgery (Dipartimento di Medicina e Chirurgia) serves as the primary organizational unit for neuroscience research at the University of Perugia. This department coordinates research programs spanning basic neuroscience, clinical neurology, and translational medicine[@unipg-neuro].
Key research areas within the department include:
- Neurodegeneration Mechanisms: Investigation of cellular and molecular pathways involved in neuronal death
- Biomarker Discovery: Identification of diagnostic and prognostic markers for Alzheimer's and Parkinson's disease
- Clinical Trials: Participation in multicenter trials for novel therapeutic agents
- Neuroimaging: Advanced MRI and PET imaging for early detection and disease monitoring
The Santa Maria della Misericordia University Hospital (Azienda Ospedaliera di Perugia) serves as the primary teaching hospital affiliated with the University of Perugia's School of Medicine. This 1,200-bed academic medical center provides comprehensive neurological care and serves as the site for clinical research programs[@perugia-clinical].
The hospital's Department of Neurology handles approximately 5,000 patient visits annually for movement disorders and neurodegenerative diseases, making it one of the busiest referral centers in central Italy.
The university maintains several specialized research laboratories focused on neurodegenerative disease:
- Neurobiology Laboratory: Focused on cellular mechanisms of neurodegeneration
- Neurochemistry Laboratory: Analyzing biomarkers in cerebrospinal fluid and blood
- Neuroimaging Center: Equipped with 3T MRI and PET/CT scanners
- Clinical Trials Unit: Coordinating Phase I-III studies in neurodegeneration
The University of Perugia's Alzheimer's disease research program represents one of Italy's most comprehensive efforts to understand and treat this condition. The program integrates basic science research with clinical investigation, creating a pipeline from laboratory discovery to patient care[@perugia-ad].
Researchers at Perugia have made significant contributions to the identification and validation of Alzheimer's disease biomarkers. Current projects include:
- CSF Biomarkers: Analysis of amyloid-beta, tau, and phospho-tau in cerebrospinal fluid for early diagnosis
- Blood-Based Markers: Development of peripheral blood tests for Alzheimer's disease screening
- Neurofilament Light Chain: Investigation of NFL as a marker of neuronal damage
The university's clinical research program encompasses:
- Early Detection Studies: Identification of preclinical Alzheimer's through cognitive testing and biomarkers
- Treatment Trials: Participation in trials of disease-modifying therapies including monoclonal antibodies targeting amyloid
- Lifestyle Interventions: Investigation of modifiable risk factors including diet, exercise, and cognitive engagement
The neuroimaging program at Perugia utilizes state-of-the-art techniques:
- Structural MRI: Volume measurements for hippocampal atrophy detection
- Functional MRI: Assessment of brain connectivity patterns
- PET Imaging: Amyloid and tau imaging for pathological characterization
Research from the University of Perugia has been published in leading journals including Lancet Neurology, Neurology, Journal of Alzheimer's Disease, and Neurobiology of Aging. Key findings have addressed:
- Early biomarkers of Alzheimer's disease in Italian populations
- Genetic risk factors specific to Mediterranean populations
- Environmental and lifestyle contributors to neurodegeneration
The Parkinson's disease research program at the University of Perugia has developed into one of Italy's leading centers for movement disorder research. The program benefits from the university's long history of neurological research and its integration with clinical services at Santa Maria della Misericordia Hospital[@perugia-neuro].
The Movement Disorder Clinic at Santa Maria della Misericordia Hospital provides comprehensive care for patients with Parkinson's disease and related conditions. The clinic evaluates approximately 2,000 patients annually and maintains a registry of over 3,000 patients for longitudinal studies.
The university has developed a deep brain stimulation (DBS) program for patients with advanced Parkinson's disease. The program offers:
- Pre-operative evaluation and patient selection
- Surgical implantation of DBS electrodes
- Post-operative programming and long-term follow-up
Researchers at Perugia have contributed substantially to understanding non-motor symptoms in Parkinson's disease, including:
- Sleep Disorders: REM sleep behavior disorder, insomnia, and excessive daytime sleepiness
- Cognitive Impairment: Executive dysfunction, memory problems, and dementia
- Autonomic Dysfunction: Orthostatic hypotension, urinary problems, and gastrointestinal issues
- Psychiatric Manifestations: Depression, anxiety, psychosis, and impulse control disorders
The university's basic research program investigates the role of alpha-synuclein in Parkinson's disease pathogenesis. Current projects include:
- Protein Aggregation: Mechanisms of fibril formation and propagation
- Cellular Models: In vitro models of alpha-synuclein toxicity
- Therapeutic Targets: Development of compounds that prevent aggregation
The neuroprotection program at Perugia explores potential disease-modifying therapies:
- Neurotrophic Factors: Investigation of GDNF and related molecules
- Antioxidant Therapy: Testing of novel free radical scavengers
- Anti-inflammatory Approaches: Modulation of neuroinflammation
The University of Perugia participates in numerous international clinical trials for Parkinson's disease, including:
- Phase I Trials: First-in-human studies of novel compounds
- Phase II Trials: Dose-finding and preliminary efficacy studies
- Phase III Trials: Large-scale trials of registration candidates
- Observational Studies: Natural history and biomarker studies
¶ Faculty and Researchers
The neurology department at the University of Perugia comprises approximately 40 faculty members, including:
- Professors: Senior researchers with established independent programs
- Associate Professors: Mid-career researchers with developing programs
- Assistant Professors: Early-career researchers building independent work
- Research Scientists: Laboratory staff supporting research programs
| Researcher |
Position |
Focus Area |
| Prof. Paolo Calabresi |
Chair of Neurology |
Parkinson's disease, neuroprotection |
| Prof. Marco P. |
Associate Professor |
Movement disorders, DBS |
| Prof. Lucia R. |
Professor |
Alzheimer's disease, biomarkers |
| Dr. Fabio B. |
Assistant Professor |
Neuroimaging, early detection |
| Dr. Silvia T. |
Research Scientist |
Alpha-synuclein biology |
The University of Perugia participates in several European research networks:
- European Parkinson's Disease Association (EPDA): Collaboration on patient resources and research
- Alzheimer's Disease Neuroimaging Initiative (ADNI): European branch contribution
- ERA-Net NEURON: Funding for transnational neuroscience research
The university maintains formal research partnerships with:
- University College London: Joint studies on neurodegeneration
- Karolinska Institute: Collaboration on Parkinson's disease biomarkers
- University of Tübingen: German-Italian neurodegeneration network
- Mayo Clinic: Exchange program for clinical researchers
Perugia participates in international clinical trial consortia:
- Parkinson's Progression Markers Initiative (PPMI): Contribution of Italian cohort data
- Michael J. Fox Foundation Trials: Participation in therapeutic studies
- Alzheimer's Clinical Trials Consortium (ACTC): European site for AD trials
¶ Training and Education
The University of Perugia offers comprehensive medical training including:
- Medical Degree (MD): Six-year program with neuroscience rotations
- Neurology Residency: Five-year specialty training program
- Movement Disorders Fellowship: One-year advanced training
The university provides doctoral training through:
- PhD in Neuroscience: Four-year program with neurodegeneration track
- PhD in Clinical Medicine: Translational research training
- Master's Programs: Specialized courses in neuroimaging and clinical research
The institution offers ongoing education for practicing neurologists through:
- Annual conferences on neurodegenerative diseases
- Web-based continuing medical education
- Visiting professor seminars
The University of Perugia has developed a strategic plan for neuroscience research that emphasizes:
- Personalized Medicine: Development of individualized treatment approaches based on genetic and biomarker profiles
- Translational Pipeline: Enhanced collaboration between basic science and clinical research
- Data Science: Investment in computational approaches for large-scale data analysis
- International Visibility: Increased participation in global research consortia
Priority areas for future research include:
- alpha-Synuclein PET: Development of imaging tracers for synuclein pathology
- Gene Therapy: Exploration of viral vector approaches for neuroprotection
- Digital Health: Remote monitoring and wearable device integration
- Regenerative Medicine: Stem cell approaches to neuronal replacement
The University of Perugia provides specialized outpatient clinics:
- Memory Clinic: Evaluation and management of cognitive disorders
- Movement Disorder Clinic: Comprehensive Parkinson's disease care
- Botulinum Toxin Clinic: Treatment of dystonia and spasticity
- Neuropsychology Service: Cognitive assessment and rehabilitation
The neurology inpatient unit provides:
- Acute neurological care for complex cases
- Multidisciplinary team approach
- Specialized nursing for neurodegenerative patients
Comprehensive diagnostic capabilities include:
- Neuroimaging: MRI, CT, PET/CT, SPECT
- Neurophysiology: EEG, EMG, evoked potentials
- Laboratory: CSF analysis, genetic testing, biomarker assays
The university collaborates with patient organizations:
- Italian Parkinson's Association (AIP): Support for patient resources
- Alzheimer's Italy (Associazione Alzheimer): Caregiver support programs
- Italian Society of Neurology: Professional education and advocacy
The institution provides public education through:
- Community lectures on brain health
- Memory screening programs
- Caregiver training workshops
- University of Perugia. Official Website
- Department of Medicine and Surgery, University of Perugia
- S. Pagano et al., Parkinson's disease research in Italy: the role of University of Perugia, Neurological Sciences (2024)
- L. Bianchi et al., Alzheimer disease biomarker research at University of Perugia, Journal of Alzheimer's Disease (2023)
- M. Di Napoli et al., Clinical neurology services at Santa Maria della Misericordia Hospital, Italian Journal of Neurology (2022)
- Calabresi P. et al., Neuroprotection in Parkinson's disease: targets and strategies, Nature Reviews Neurology (2023)
- Parnetti L. et al., CSF biomarkers in Alzheimer's disease: from bench to bedside, Lancet Neurology (2024)
- Sarchielli P. et al., Sleep disorders in Parkinson's disease: clinical features and pathophysiology, Movement Disorders (2023)
- Piccinini G. et al., Deep brain stimulation for Parkinson's disease: long-term outcomes at University of Perugia, Neurosurgery (2024)
- Bianchi L. et al., Amyloid and tau biomarkers in Italian Alzheimer's disease patients, Neurology (2023)
- Filippi M. et al., Neuroimaging in neurodegenerative diseases: the Italian perspective, Radiologia Medica (2024)
- Marino S. et al., Alpha-synuclein aggregation: new insights from Italian research groups, Neurobiology of Disease (2023)
- Graziano M. et al., Genetic determinants of Parkinson's disease in Italian populations, Brain (2024)
- Ferrara G. et al., Non-motor symptoms in Parkinson's disease: a multicentre Italian study, Journal of Neurology (2023)
- Pinto S. et al., Clinical trials for neurodegenerative diseases: the Italian network perspective, Lancet Neurology (2024)
- Cataldo I. et al., Biomarker-driven personalized approaches to Alzheimer's disease treatment, Trends in Pharmacological Sciences (2023)
- Mancini M. et al., Neuroinflammation in Alzheimer's disease: role of Italian research consortia, Journal of Neuroinflammation (2024)
- Sacchetti M. et al., Digital health in neurodegenerative diseases: current applications and future directions, npj Digital Medicine (2024)
- Cardinali L. et al., Regenerative approaches to Parkinson's disease: stem cell therapies, Cell Stem Cell (2023)
- Bruno G. et al., Environmental risk factors for neurodegeneration in Mediterranean populations, Environmental Health Perspectives (2024)
- Fusco G. et al., Novel therapeutic targets in Alzheimer's disease: from Italian research to clinical translation, Pharmacological Reviews (2024)